Use Cases
Growth Hormone
Body Composition and Sleep Quality
Growth-hormone secretagogues are used for the same reason across the board: better sleep first, body composition later.
CEarly Human ResearchReviewed September 1, 2026
Compounds used for this goal
The reason
Why people use it
- Deeper sleep in the first weeks is the most consistently reported subjective effect, which fits the physiology — most growth hormone release happens during slow-wave sleep.
- The stated goal is usually a modest recomposition: less visceral fat, slightly more lean mass, without the supraphysiological exposure of injected growth hormone itself.
- Secretagogues preserve pulsatile release and feedback, which is the mechanistic argument people make for preferring them over exogenous growth hormone.
The evidence
What the research shows
- Tesamorelin is the outlier with real human evidence: randomised trials in HIV-associated lipodystrophy reported reduced visceral adipose tissue, and it holds an approved indication.
- Sermorelin has human pharmacology and historical diagnostic use, so the growth-hormone response itself is well documented.
- CJC-1295 and ipamorelin have human pharmacokinetic and hormone-response data, but no trials examining long-term body composition, sleep architecture or safety. The paired blend has never been studied as a blend.
- Where growth hormone axis stimulation has been studied long-term, insulin sensitivity worsening and fluid retention are recurring findings.
Reported use
How it is reported to be used
- Reported use is almost always an evening subcutaneous injection, timed to align with natural nocturnal release.
- Sleep changes are described within days to weeks; any body-composition change is described over months, which is consistent with hormone physiology.
- Water retention, tingling in the hands and increased hunger — ipamorelin and GHRP-family compounds affect appetite signalling — are the most reported effects.
Our reading
Evidence verdict
CEarly Human ResearchSmall, early-phase or single-centre human studies only. Findings are preliminary.
Mixed within the group. Approved and trial-supported for tesamorelin in a narrow indication; early human pharmacology only for CJC-1295 and ipamorelin, with no outcome data.
Before you read further
Cautions and open questions
- Growth hormone axis stimulation can raise blood glucose and reduce insulin sensitivity; this is documented, not theoretical.
- Long-term consequences of sustained IGF-1 elevation in healthy adults are unstudied.
- Prohibited in competitive sport as growth hormone secretagogues.
Sources
Referenced research
- Randomised controlled trial2010
Tesamorelin and visceral adipose tissue in lipodystrophy
- Main finding
- Reported reduced visceral adipose tissue versus placebo over 26 to 52 weeks.
- Narrative review
Growth hormone secretagogues: pharmacology and open questions
Educational content only. This page is not medical advice, a protocol or an individualised dosing recommendation. Reported use patterns summarise published literature and community reporting; they are not verified clinical cases and are not endorsements. Speak to a qualified healthcare professional about your own health.
All use cases